[en] Transcatheter aortic valve implantation (TAVI) has become the method of choice for patients with severe aortic valve stenosis, who are ineligible or at high risk for surgery. In this high risk patient population, early and late mortality and rehospitalization rates after TAVI are still relatively high. In spite of recent improvements in procedural TAVI, and establishment of risk models for poor outcome, determining individual risk remains challenging. In this context, current data from several small studies strongly suggest that blood biomarkers of myocardial injury, cardiac mechanical stretch, inflammation, and hemostasis imbalance might play an important role by providing informations on patient risk at baseline, and postprocedural progression of patient clinical conditions from days up to years post-TAVI. Although the role of biomarkers for predicting survival post-TAVI remains to be validated in large randomized studies, implementing biomarkers in clinical practice might improve risk stratification, thereby further reducing TAVI-associated morbidity and mortality.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Oury, Cécile ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : GIGA - Cardiovascular Sciences
Nchimi Longang, Alain ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Bergler-Klein, Jutta
Language :
English
Title :
Can Blood Biomarkers Help Predicting Outcome in Transcatheter Aortic Valve Implantation?
Publication date :
2018
Journal title :
Frontiers in Cardiovascular Medicine
eISSN :
2297-055X
Publisher :
Frontiers Research Foundation, Lausanne, Switzerland
Murashita T, Greason KL, Suri RM, Nkomo VT, Holmes DR, Rihal CS, et al. Aortic valve replacement for severe aortic valve stenosis in the nonagenarian patient. Ann Thorac Surg (2014) 98(5):1593–7. 10.1016/j.athoracsur.2014.06.015
Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med (2010) 363(17):1597–607. 10.1056/NEJMoa1008232
Tamburino C, Capodanno D, Ramondo A, Petronio AS, Ettori F, Santoro G, et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation (2011) 123(3):299–308. 10.1161/CIRCULATIONAHA.110.946533
Rodés-Cabau J, Webb JG, Cheung A, Ye J, Dumont E, Osten M, et al. Long-term outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience. J Am Coll Cardiol (2012) 60(19):1864–75. 10.1016/j.jacc.2012.08.960
Arnold SV, Reynolds MR, Lei Y, Magnuson EA, Kirtane AJ, Kodali SK, et al. Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation (2014) 129(25):2682–90. 10.1161/CIRCULATIONAHA.113.007477
Arnold SV, Afilalo J, Spertus JA, Tang Y, Baron SJ, Jones PG, et al. Prediction of poor outcome after transcatheter aortic valve replacement. J Am Coll Cardiol (2016) 68(17):1868–77. 10.1016/j.jacc.2016.07.762
Edwards FH, Cohen DJ, O'Brien SM, Peterson ED, Mack MJ, Shahian DM, et al. Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. JAMA Cardiol (2016) 1(1):46–52. 10.1001/jamacardio.2015.0326
Puri R, Iung B, Cohen DJ, Rodés-Cabau J. TAVI or No TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. Eur Heart J (2016) 37(28):2217–25. 10.1093/eurheartj/ehv756
Ribeiro HB, Dahou A, Urena M, Carrasco JL, Mohammadi S, Doyle D, et al. Myocardial injury after transaortic versus transapical transcatheter aortic valve replacement. Ann Thorac Surg (2015a) 99(6):2001–9. 10.1016/j.athoracsur.2015.01.029
Rodés-Cabau J, Gutiérrez M, Bagur R, de Larochellière R, Doyle D, Côté M, et al. Incidence, predictive factors, and prognostic value of myocardial injury following uncomplicated transcatheter aortic valve implantation. J Am Coll Cardiol (2011) 57(20):1988–99. 10.1016/j.jacc.2010.11.060
Yong ZY, Wiegerinck EM, Boerlage-van Dijk K, Koch KT, Vis MM, Bouma BJ, et al. Predictors and prognostic value of myocardial injury during transcatheter aortic valve implantation. Circ Cardiovasc Interv (2012) 5(3):415–23. 10.1161/CIRCINTERVENTIONS.111.964882
Barbash IM, Dvir D, Ben-Dor I, Badr S, Okubagzi P, Torguson R, et al. Prevalence and effect of myocardial injury after transcatheter aortic valve replacement. Am J Cardiol (2013) 111(9):1337–43. 10.1016/j.amjcard.2012.12.059
Paradis JM, Maniar HS, Lasala JM, Kodali S, Williams M, Lindman BR, et al. Clinical and functional outcomes associated with myocardial injury after transfemoral and transapical transcatheter aortic valve replacement: a subanalysis from the PARTNER trial (placement of aortic transcatheter valves). JACC Cardiovasc Interv (2015) 8(11):1468–79. 10.1016/j.jcin.2015.06.018
Ribeiro HB, Larose É, de La Paz Ricapito M, Le Ven F, Nombela-Franco L, Urena M, et al. Myocardial injury following transcatheter aortic valve implantation: insights from delayed-enhancement cardiovascular magnetic resonance. EuroIntervention (2015b) 11(2):205–13. 10.4244/EIJV11I2A39
Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 60(15):1438–54. 10.1016/j.jacc.2012.09.001
Ribeiro HB, Nombela-Franco L, Muñoz-García AJ, Lemos PA, Amat-Santos I, Serra V, et al. Predictors and impact of myocardial injury after transcatheter aortic valve replacement: a multicenter registry. J Am Coll Cardiol (2015c) 66(19):2075–88. 10.1016/j.jacc.2015.08.881
Koskinas KC, Stortecky S, Franzone A, O'Sullivan CJ, Praz F, Zuk K, et al. Post-procedural troponin elevation and clinical outcomes following transcatheter aortic valve implantation. J Am Heart Assoc (2016) 5(2):e002430. 10.1161/JAHA.115.002430
Chorianopoulos E, Krumsdorf U, Geis N, Pleger ST, Giannitsis E, Katus HA, et al. Preserved prognostic value of preinterventional troponin T levels despite successful TAVI in patients with severe aortic stenosis. Clin Res Cardiol (2014) 103(1):65–72. 10.1007/s00392-013-0624-8
O'Neill BP, Guerrero M, Thourani VH, Kodali S, Heldman A, Williams M, et al. Prognostic value of serial B-type natriuretic peptide measurement in transcatheter aortic valve replacement (from the PARTNER Trial). Am J Cardiol (2015) 115(9):1265–72. 10.1016/j.amjcard.2015.01.561
Gotzmann M, Czauderna A, Aweimer A, Hehnen T, Bösche L, Lind A, et al. B-type natriuretic peptide is a strong independent predictor of long-term outcome after transcatheter aortic valve implantation. J Heart Valve Dis (2014) 23(5):537–44.
Koskinas KC, O'Sullivan CJ, Heg D, Praz F, Stortecky S, Pilgrim T, et al. Effect of B-type natriuretic peptides on long-term outcomes after transcatheter aortic valve implantation. Am J Cardiol (2015) 116(10):1560–5. 10.1016/j.amjcard.2015.08.016
Frank D, Stark S, Lutz M, Weissbrodt A, Freitag-Wolf S, Petzina R, et al. Preprocedural high-sensitive troponin predicts survival after transcatheter aortic valve implantation (TAVI). Int J Cardiol (2013) 169(3):e38–9. 10.1016/j.ijcard.2013.08.108
Koifman E, Garcia-Garcia HM, Alraies MC, Buchanan K, Hideo-Kajita A, Steinvil A, et al. Correlates and significance of elevation of cardiac biomarkers elevation following transcatheter aortic valve implantation. Am J Cardiol (2017) 120(5):850–6. 10.1016/j.amjcard.2017.05.059
Liebetrau C, Kim WK, Meyer A, Arsalan M, Gaede L, Blumenstein JM, et al. Identification of periprocedural myocardial infarction using a high-sensitivity troponin i assay in patients who underwent transcatheter aortic valve implantation. Am J Cardiol (2017) 120(7):1180–6. 10.1016/j.amjcard.2017.06.069
Bergler-Klein J, Gyöngyösi M, Maurer G. The role of biomarkers in valvular heart disease: focus on natriuretic peptides. Can J Cardiol (2014) 30(9):1027–34. 10.1016/j.cjca.2014.07.014
Henri C, Magne J, Dulgheru R, Davin L, Laaraibi S, Voilliot D, et al. Use fulness of serial B-type natriuretic peptide assessment in asymptomatic aortic stenosis. Am J Cardiol (2014) 114(3):441–8. 10.1016/j.amjcard.2014.04.053
Shen M, Tastet L, Bergler-Klein J, Pibarot P, Clavel MA. Blood, tissue and imaging biomarkers in calcific aortic valve stenosis: past, present and future. Curr Opin Cardiol (2018) 33(2):125–33. 10.1097/HCO.0000000000000487
Pfister R, Wahlers T, Baer FM, Scherner M, Strauch J, Erdmann E. Utility of NT-pro-BNP in patients undergoing transapical aortic valve replacement. Clin Res Cardiol (2010) 99(5):301–7. 10.1007/s00392-010-0118-x
Ben-Dor I, Minha S, Barbash IM, Aly O, Dvir D, Deksissa T, et al. Correlation of brain natriuretic peptide levels in patients with severe aortic stenosis undergoing operative valve replacement or percutaneous transcatheter intervention with clinical, echocardiographic, and hemodynamic factors and prognosis. Am J Cardiol (2013) 112(4):574–9. 10.1016/j.amjcard.2013.04.023
Dworakowski R, Wendler O, Bhan A, Smith L, Pearson P, Alcock E, et al. Successful transcatheter aortic valve implantation (TAVI) is associated with transient left ventricular dysfunction. Heart (2012) 98(22):1641–6. 10.1136/heartjnl-2012-302505
Stähli BE, Gebhard C, Saleh L, Falk V, Landmesser U, Nietlispach F, et al. N-terminal pro-B-type natriuretic peptide-ratio predicts mortality after transcatheter aortic valve replacement. Catheter Cardiovasc Interv (2015) 85(7):1240–7. 10.1002/ccd.25788
Baldenhofer G, Laule M, Mockel M, Sanad W, Knebel F, Dreger H, et al. Mid-regional pro-adrenomedullin (MR-proADM) and mid-regional pro-atrial natriuretic peptide (MR-proANP) in severe aortic valve stenosis: association with outcome after transcatheter aortic valve implantation (TAVI). Clin Chem Lab Med (2017) 55(2):275–83. 10.1515/cclm-2015-0419
Rheude T, Pellegrini C, Schmid H, Trenkwalder T, Mayr NP, Joner M, et al. Comparison of carbohydrate antigen 125 and N-terminal pro-brain natriuretic peptide for risk prediction after transcatheter aortic valve implantation. Am J Cardiol (2018) 121(4):461–8. 10.1016/j.amjcard.2017.11.020
Sinning JM, Wollert KC, Sedaghat A, Widera C, Radermacher MC, Descoups C, et al. Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement. Am Heart J (2015) 170(4):821–9. 10.1016/j.ahj.2015.07.003
Lindman BR, Breyley JG, Schilling JD, Vatterott AM, Zajarias A, Maniar HS, et al. Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. Heart (2015a) 101(17):1382–8. 10.1136/heartjnl-2015-307742
Hagström E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S, et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J (2016) 37(16):1325–33. 10.1093/eurheartj/ehv491
Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, et al. Growth differentiation factor 15 at 1 month after an acute coronary syndrome is associated with increased risk of major bleeding. J Am Heart Assoc (2017) 6(4):e005580. 10.1161/JAHA.117.005580
Dieplinger B, Mueller T. Soluble ST2 in heart failure. Clin Chim Acta (2015) 443:57–70. 10.1016/j.cca.2014.09.021
Weinberg EO, Shimpo M, de Keulenaer GW, Macgillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation (2002) 106(23):2961–6. 10.1161/01.CIR.0000038705.69871.D9
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 62(16):e147–239. 10.1016/j.jacc.2013.05.019
Lancellotti P, Dulgheru R, Magne J, Henri C, Servais L, Bouznad N, et al. Elevated plasma soluble ST2 Is associated with heart failure symptoms and outcome in aortic stenosis. PLoS ONE (2015) 10(9):e0138940. 10.1371/journal.pone.0138940
Wernly B, Lichtenauer M, Jirak P, Eder S, Reiter C, Kammler J, et al. Soluble ST2 predicts 1-year outcome in patients undergoing transcatheter aortic valve implantation. Eur J Clin Invest (2017) 47(2):149–57. 10.1111/eci.12719
Stundl A, Lünstedt NS, Courtz F, Freitag-Wolf S, Frey N, Holdenrieder S, et al. Soluble ST2 for risk stratification and the prediction of mortality in patients undergoing transcatheter aortic valve implantation. Am J Cardiol (2017) 120(6):986–93. 10.1016/j.amjcard.2017.06.033
Schmid J, Stojakovic T, Zweiker D, Scharnagl H, Maderthaner RD, Scherr D, et al. ST2 predicts survival in patients undergoing transcatheter aortic valve implantation. Int J Cardiol (2017) 244:87–92. 10.1016/j.ijcard.2017.06.066
Rouzaud-Laborde C, Delmas C, Pizzinat N, Tortosa F, Garcia C, Mialet-Perez J, et al. Platelet activation and arterial peripheral serotonin turnover in cardiac remodeling associated to aortic stenosis. Am J Hematol (2015) 90(1):15–19. 10.1002/ajh.23855
Natorska J, Bykowska K, Hlawaty M, Marek G, Sadowski J, Undas A. Increased thrombin generation and platelet activation are associated with deficiency in high molecular weight multimers of von Willebrand factor in patients with moderate-to-severe aortic stenosis. Heart (2011) 97(24):2023–8. 10.1136/hrt.2010.217273
Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med (2003) 349(4):343–9. 10.1056/NEJMoa022831
Dvir D, Généreux P, Barbash IM, Kodali S, Ben-Dor I, Williams M, et al. Acquired thrombocytopenia after transcatheter aortic valve replacement: clinical correlates and association with outcomes. Eur Heart J (2014) 35(38):2663–71. 10.1093/eurheartj/ehu082
Mitrosz M, Kazimierczyk R, Sobkowicz B, Waszkiewicz E, Kralisz P, Frank M, et al. The causes of thrombocytopenia after transcatheter aortic valve implantation. Thromb Res (2017) 156:39–44. 10.1016/j.thromres.2017.05.020
Gallet R, Seemann A, Yamamoto M, Hayat D, Mouillet G, Monin JL, et al. Effect of transcatheter (via femoral artery) aortic valve implantation on the platelet count and its consequences. Am J Cardiol (2013) 111(11):1619–24. 10.1016/j.amjcard.2013.01.332
Sedaghat A, Falkenberg N, Sinning JM, Kulka H, Hammerstingl C, Nickenig G, et al. TAVI induces an elevation of hemostasis-related biomarkers, which is not causative for post-TAVI thrombocytopenia. Int J Cardiol (2016) 221:719–25. 10.1016/j.ijcard.2016.07.094
Amabile N, Azmoun A, Ghostine S, Ramadan R, Haddouche Y, Raoux F, et al. Incidence, predictors and prognostic value of serious hemorrhagic complications following transcatheter aortic valve implantation. Int J Cardiol (2013) 168(1):151–6. 10.1016/j.ijcard.2012.09.025
Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg (2013) 145(1):6–23. 10.1016/j.jtcvs.2012.09.002
Huczek Z, Kochman J, Kowara MK, Wilimski R, Scislo P, Scibisz A, et al. Baseline platelet indices and bleeding after transcatheter aortic valve implantation. Blood Coagul Fibrinolysis (2015) 26(5):527–32. 10.1097/MBC.0000000000000283
Bath P, Algert C, Chapman N, Neal B, PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke (2004) 35(3):622–6. 10.1161/01.STR.0000116105.26237.EC
Huczek Z, Kochman J, Filipiak KJ, Horszczaruk GJ, Grabowski M, Piatkowski R, et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol (2005) 46(2):284–90. 10.1016/j.jacc.2005.03.065
Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost (2010) 8(1):148–56. 10.1111/j.1538-7836.2009.03584.x
Gul M, Uyarel H, Akgul O, Uslu N, Yildirim A, Eksik A, et al. Hematologic and clinical parameters after transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis. Clin Appl Thromb Hemost (2014) 20(3):304–10. 10.1177/1076029612462762
Bolliger D, dell-Kuster S, Seeberger MD, Tanaka KA, Gregor M, Zenklusen U, et al. Impact of loss of high-molecular-weight von Willebrand factor multimers on blood loss after aortic valve replacement. Br J Anaesth (2012) 108(5):754–62. 10.1093/bja/aer512
van Belle E, Rauch A, Vincent F, Robin E, Kibler M, Labreuche J, et al. Von willebrand factor multimers during transcatheter aortic-valve replacement. N Engl J Med (2016) 375(4):335–44. 10.1056/NEJMoa1505643
Polzin A, Schleicher M, Seidel H, Scharf RE, Merx MW, Kelm M, et al. High on-treatment platelet reactivity in transcatheter aortic valve implantation patients. Eur J Pharmacol (2015) 751:24–7. 10.1016/j.ejphar.2015.01.028
Orvin K, Eisen A, Perl L, Zemer-Wassercug N, Codner P, Assali A, et al. Platelet reactivity in patients undergoing transcatheter aortic valve implantation. J Thromb Thrombolysis (2016) 42(1):11–18. 10.1007/s11239-015-1322-3
Rodés-Cabau J, Masson JB, Welsh RC, Garcia del Blanco B, Pelletier M, Webb JG, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation) randomized clinical trial. JACC Cardiovasc Interv (2017) 10(13):1357–65. 10.1016/j.jcin.2017.04.014
Roberts DI, Nawarskas JJ. Treatment options for patients with poor clopidogrel response. Cardiol Rev (2013) 21(6):309–17. 10.1097/CRD.0b013e3182a72fab
Sexton TR, Wallace EL, Chen A, Charnigo RJ, Reda HK, Ziada KM, et al. Thromboinflammatory response and predictors of outcomes in patients undergoing transcatheter aortic valve replacement. J Thromb Thrombolysis (2016) 41(3):384–93. 10.1007/s11239-015-1326-z
Lindman BR, Goldstein JS, Nassif ME, Zajarias A, Novak E, Tibrewala A, et al. Systemic inflammatory response syndrome after transcatheter or surgical aortic valve replacement. Heart (2015b) 101(7):537–45. 10.1136/heartjnl-2014-307057
